摘要
目的:探究生长抑素、乌司他汀联合氧化苦参碱对重症胰腺炎肠粘膜屏障损伤的改善及HMGB1水平的影响。方法:随机选取120例重症胰腺炎患者作为研究对象,简单随机分组分为观察组与对照组。对照组予以基础治疗,观察组在对照组基础上联合氧化苦参碱治疗。观察两组患者白细胞恢复正常时间、炎症因子水平、肠黏膜屏障损伤指标水平。结果:观察组治疗总有效率为93.33%显著高于对照组,P<0.05;观察组腹痛缓解时间(3.58±1.02)d、首次排便时间(3.09±0.68)d、血淀粉酶恢复正常时间(4.58±1.45)d、白细胞恢复正常时间(5.05±1.33)d均显著低于对照组,P<0.05;治疗后,观察组TNF-α(887.65±133.24)ng/L、IL-6(64.75±22.31)ng/L、IL-1(388.65±83.06)ng/L、HMGB1(32.43±23.67)μg/mL均显著低于对照组水平,P<0.05;治疗后,观察组患者血清DAO(8.16±2.04)U/L、血清D-乳酸(6.51±0.53)mg/L、肉毒素(16.42±6.87)EU/L均显著低于对照组水平,P<0.05。结论:针对重症胰腺炎患者予以氧化苦参碱联合基础治疗,临床疗效显著,可显著降低炎症因子水平,改善患者肠黏膜屏障功能,值得临床推广使用。
Objective:To investigate the effect of oxymatrine on intestinal mucosal barrier damage and HMGB1 level in patients with severe pancreatitis.Methods:A total of 120 patients with severe pancreatitis were selected as the research object,and were randomly vided into observation group and control group.The control group was given basic treatment,while the observation group was treated with Oxymatrine on the basis of the control group.The white blood cell recovery time,inflammatory factor level and intestinal mucosal barrier damage index level were observed.Results:The total effective rate of observation group was 93.33%,which was significantly higher than that of control group,P<0.05;The abdominal pain relief time(3.58±1.02)d,first defecation time(3.09±0.68)d,blood amylase recovery time(4.58±1.45)d and white blood cell recovery time(5.05±1.33)d in the observation group were significantly lower,P<0.05;After treatment,the levels of TNF-α(887.65±133.24)ng/L,IL-6(64.75±22.31)ng/L,IL-1(388.65±83.06)ng/L and HMGB1(32.43±23.67)μg/mL in the observation group were significantly lower,P<0.05;After treatment,the levels of serum DAO(8.16±2.04)U/L,serum D-lactic acid(6.51±0.53)mg/L and botulinum toxin(16.42±6.87)EU/L in the observation group were significantly lower,P<0.05.Conclusion:Oxymatrine combined with basic treatment for severe pancreatitis has significant clinical effect,can significantly reduce the level of inflammatory factors,improve the intestinal mucosal barrier function of patients,and is worthy of clinical application.
作者
马德渊
李山林
李艳秋
Ma Deyuan(Xining First People's Hospital, Qinghai Xining 810000, China)
出处
《河北医学》
CAS
2020年第11期1877-1881,共5页
Hebei Medicine
基金
青海省卫生厅重点专科项目,(编号:2018015943)。
